Ophthalmology. Retina最新文献

Spontaneous Remodeling of Abnormal Choroidal Vasculature.

IF 4.4

Ophthalmology. Retina Pub Date : 2025-02-21 DOI: 10.1016/j.oret.2025.01.003

Eliza Anthony, Jefila Jayakumar, Prabu Baskaran

引用次数: 0

Reply.

IF 4.4

Ophthalmology. Retina Pub Date : 2025-02-20 DOI: 10.1016/j.oret.2025.01.014

Cindy X Cai, Akihiko Nishimura, George Hripcsak

引用次数: 0

Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics network study (Ophthalmol Retina. 2024;8:733-743.).

IF 4.4

Ophthalmology. Retina Pub Date : 2025-02-20 DOI: 10.1016/j.oret.2025.01.013

Flora Lum

引用次数: 0

Intra-arterial chemotherapy for retinoblastoma, outcomes analysis in 357 eyes: 13 years of experience in a referral center in Brazil.

IF 4.4

Ophthalmology. Retina Pub Date : 2025-02-17 DOI: 10.1016/j.oret.2025.02.013

Luiz F Teixeira, Carla R P D Macedo, José R F Fonseca, Bruna Morales, Monique K Mangeon, Bruno A Miranda, Ricardo Casaroli-Marano, Juliana M F Sallum

{"title":"Intra-arterial chemotherapy for retinoblastoma, outcomes analysis in 357 eyes: 13 years of experience in a referral center in Brazil.","authors":"Luiz F Teixeira, Carla R P D Macedo, José R F Fonseca, Bruna Morales, Monique K Mangeon, Bruno A Miranda, Ricardo Casaroli-Marano, Juliana M F Sallum","doi":"10.1016/j.oret.2025.02.013","DOIUrl":"https://doi.org/10.1016/j.oret.2025.02.013","url":null,"abstract":"Objective: Evaluate the outcomes of intra-arterial chemotherapy (IAC) for the treatment of naive and non-naive retinoblastoma eyes. Ocular survival rates, risk factors for enucleation, ocular complications, metastatic disease, and overall survival were analyzed.Design: A retrospective, single-institution study PARTICIPANTS: A total of 300 patients treated with IAC between April 2010 and April 2023 were included.Interventions: During IAC infusions, 1-3 drugs were used (melphalan, 3.0-7.5mg; topotecan, 0.3-2.0 mg; carboplatin, 20-50 mg). Adjuvant therapy was used as needed to consolidate treatment.Main outcome measures: Ocular survival rates, ocular complications, and the risk factors for enucleation were measured.Results: A total of 357 eyes were treated with 1,536 IAC infusions, with a median of four cycles per eye, and followed for 60.69 months. The Kaplan-Meier estimates for the overall ocular survival were 90% at 1, 89% at 2, and 86% at 5 years. No difference in ocular survival was found between IAC indications (primary 88% vs secondary 85% vs bridge 89%; p = 0.52) or for the use of tandem therapy (tandem 85% vs no tandem 87%; p = 0.93). Intravitreal chemotherapy as adjuvant therapy was used in 31.37% and plaque therapy in 5% of the eyes. The group did not receive external beam radiation. Univariable and multivariable analyses showed that the presence of subretinal seeds was significantly associated with an increased risk of enucleation, and the use of ophthalmic artery (OA) ostium in >50% of infusions per eye was a protective factor to avoid enucleation. Retinal and/or choroidal vascular, ischemic, or atrophic effects were the most frequent complications found in 5.0% of the eyes. Metastatic disease was observed in 0.33% of the patients. The overall 5-year patient survival was 99.3%.Conclusions: The use of IAC in different indications (primary, secondary, bridge, and tandem) to treat naive or recurrent-refractory retinoblastomas showed successful results. Most eyes were preserved. Subretinal seeds at presentation were associated with a high enucleation risk. The use of the OA ostium for drug delivery avoided enucleation.","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intravitreal Silicone Oil Bubbles after Perforating Needlestick Open-Globe Injury.

IF 4.4

Ophthalmology. Retina Pub Date : 2025-02-17 DOI: 10.1016/j.oret.2025.01.009

Taariq K Mohammed, Jonathan F Russell

引用次数: 0

Extensive Myelinated Nerve Fibers in a Case of Straatsma Syndrome.

IF 4.4

Ophthalmology. Retina Pub Date : 2025-02-17 DOI: 10.1016/j.oret.2025.01.005

Gulshan Barwar

引用次数: 0

Follow-up Algorithm after Bevacizumab Treatment for Retinopathy of Prematurity.

IF 4.4

Ophthalmology. Retina Pub Date : 2025-02-13 DOI: 10.1016/j.oret.2025.02.010

Maram Isaac, Kamiar Mireskandari, Peter J Kertes, Nasrin N Tehrani

引用次数: 0

Low Dose Bevacizumab 0.03 mg for Treatment of Type I Retinopathy of Prematurity.

IF 4.4

Ophthalmology. Retina Pub Date : 2025-02-12 DOI: 10.1016/j.oret.2025.02.009

Thomas W Hejkal, Shruti Sinha, Pukhraj Rishi, Samiksha F Jain, Paul J Rychwalski

{"title":"Low Dose Bevacizumab 0.03 mg for Treatment of Type I Retinopathy of Prematurity.","authors":"Thomas W Hejkal, Shruti Sinha, Pukhraj Rishi, Samiksha F Jain, Paul J Rychwalski","doi":"10.1016/j.oret.2025.02.009","DOIUrl":"https://doi.org/10.1016/j.oret.2025.02.009","url":null,"abstract":"Purpose: We reviewed outcomes using intravitreal bevacizumab 0.03 mg to treat retinopathy of prematurity (ROP) after switching to this dose in November 2018.Design: Multi-center, retrospective, non-randomized, non-masked, consecutive case series.Methods: Results from 62 patients (123 eyes) treated between November 2018 and September 2023 with low-dose intravitreal bevacizumab, 0.03 mg in 0.03 ml, by four treating physicians were reviewed.Main outcome measures: Primary outcome measures were percentage of eyes having initial regression of ROP and percentage of eyes that received subsequent laser treatment. Secondary outcomes were time between bevacizumab and subsequent laser treatment, number of laser spots, and percentage with recurrence of ROP.Results: All eyes had initial regression of ROP. Of the 123 eyes, 42 (34%) received laser treatment at some point after bevacizumab; 34 (28%) for persistent avascular retina (PAR) and 8 (7%) for reactivation of ROP. The average time between bevacizumab and laser was 16 ± 6 weeks for PAR and 13 ± 5.8 weeks for recurrent ROP. The mean number of laser spots per eye was 496 ± 247 for PAR and 905 ± 915 for recurrent ROP (p = 0.028). No eyes developed stage 4 or stage 5 ROP.Conclusion: Based on historical comparisons, a 0.03-mg dose of intravitreal bevacizumab was as effective as a 0.625-mg dose for treatment of ROP. These data provide additional evidence from clinical practice to support the use of a 0.03-mg dose of bevacizumab for treatment of ROP.","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply.

IF 4.4

Ophthalmology. Retina Pub Date : 2025-02-09 DOI: 10.1016/j.oret.2025.01.002

Jawad Muayad, Asad Loya, Zain S Hussain, Debora H Lee, Muhammad Z Chauhan, Andrew G Lee, Asadolah Movahedan, Sami S Dahr

引用次数: 0

Re: Muayad et al.: Influence of common medications on diabetic macular edema in type 2 diabetes mellitus (Ophthalmol Retina. 2024 Dec 5:S2468-6530(24)00582-7. doi: 10.1016/j.oret.2024.12.006. Online ahead of print.).

IF 4.4

Ophthalmology. Retina Pub Date : 2025-02-09 DOI: 10.1016/j.oret.2025.01.001

Wan-Ju Annabelle Lee

引用次数: 0